Bio-Techne price target raised to $90 from $88 at Scotiabank

Scotiabank analyst Sung Ji Nam raised the firm’s price target on Bio-Techne (TECH) to $90 from $88 and keeps an Outperform rating on the shares. The company’s Q2 results beat on the top and bottom lines, with earlier-than-expected pickup in demand from large biopharma, the analyst tells investors. While the company did not provide guidance, management’s outlook for the second half of the year remains in-tact, the firm adds.